Available Pharmacological Methods of Obesity Treatment Worldwide - Drugs Review
DOI:
https://doi.org/10.12775/QS.2025.39.58412Keywords
obesity, obesity treatment, FDA, EMA, drugs mechanism, side effectsAbstract
Introduction and Purpose: The prevalence of obesity is increasing year by year all over the world. Along with the progression of the disease, there is also progress in the pharmacotherapy of obesity. The developing epidemic of obesity indicates that non-pharmacological methods are not able to solve this problem. For over 60 years, there has been a search for the ideal drug that would allow not only weight loss but also maintaining a lower bodyweight and reducing the cardiovascular risk that obesity carries. It is very important to thoroughly examine the intricacies and impact of the drugs used in order to properly select the drug for each case individually, depending on the source of obesity. The aim of this review is to present the available drugs together with the mechanism of their actions and the side effects associated with their use.
Brief Description of the State of Knowledge: There are currently 7 drugs approved by the Food and Drug Administration (FDA) and 6 approved by the European Medicines Agency (EMA) for long-term (over 12 weeks) treatment of obesity. All available drugs are prescribed for patients with a body mass index of≥ 30 kg/m2 or ≥ 27 kg/m2 with concomitant comorbidity. However, their use should be combined with intervention in the lifestyle of the patients.
Summary: Obesity affects a large part of society and the number of patients is still growing. This global problem is a therapeutic challenge for doctors. A properly selected drug for the patient's needs may prove to be crucial in the treatment of obesity.
Materials and Methods: The literature review was conducted using the Google Scholar database
References
Hachuła, M., Kosowski, M., Zielańska, K., Basiak, M., & Okopień, B. (2023). The Impact of Various Methods of Obesity Treatment on the Quality of Life and Mental Health—A Narrative Review. International journal of environmental research and public health, 20(3), 2122.
https://doi.org/10.3390/ijerph20032122
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2024). What is the pipeline for future medications for obesity? International Journal of Obesity, 1-19.
https://doi.org/10.1038/s41366-024-01473-y
Tchang, B. G., Aras, M., Kumar, R. B., & Aronne, L. J. (2024). Pharmacologic treatment of overweight and obesity in adults. Endotext [Internet].
Sundbom, M., Järvholm, K., Sjögren, L., Nowicka, P., & Lagerros, Y. T. (2024). Obesity treatment in adolescents and adults in the era of personalized medicine. Journal of internal medicine, 296(2), 139-155.
https://doi.org/10.1111/joim.13816
Yes, Y. J., & Lee, S. Y. (2021). Long-term efficacy and safety of anti-obesity treatment: where do we stand? Current obesity reports, 10, 14-30.
https://doi.org/10.1007/s13679-020-00422-w
Hollander, P., Bays, H. E., Rosenstock, J., Frustaci, M. E., Fung, A., Vercruysse, F., & Erondu, N. (2017). Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial. Diabetes Care, 40(5), 632-639.
https://doi.org/10.2337/dc16-2427
Topaloglu, O., & Sahin, I. (2021). Pharmacological treatment of obesity in clinical practice. Med-Science, 10(2), 651-657.
DOI: 10.5455/medscience.2021.05.151
Czopek, A., Zagórska, A., & Pawłowski, M. (2016). Przegląd najważniejszych preparatów stosowanych w leczeniu otyłości. Medicina Internacia Revuo, 27(106), 20-25.
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023). Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine, 58.
DOI: 10.1016/j.eclinm.2023.101882
Wajid, I., Vega, A., Thornhill, K., Jenkins, J., Merriman, C., Chandler, D., ... & Kaye, A. D. (2023). Topiramate (Topamax): Evolving role in weight reduction management: a narrative review. Life, 13(9), 1845.
https://doi.org/10.3390/life13091845
Bays, H. E., Hsia, D. S., Nguyen, L. T., Peterson, C. A., & Varghese, S. T. (2024). Effects of phentermine/topiramate extended-release, phentermine, and placebo on ambulatory blood pressure monitoring in adults with overweight or obesity: A randomized, multicenter, double-blind study. Obesity Pillars, 9, 100099.
https://doi.org/10.1016/j.obpill.2024.100099
Sherman, M. M., Ungureanu, S., & Rey, J. A. (2016). Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults. Pharmacy and Therapeutics, 41(3), 164.
Raźniewska, K. Safety of liraglutide use in the treatment of overweight and obesity.
DOI: 10.53139/FW.20241722
Qamar, S., Mallik, R., & Makaronidis, J. (2024). Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction. touchREVIEWS in Endocrinology, 20(2), 62.
https://doi.org/10.17925/EE.2024.20.2.9
Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023). Semaglutide for the treatment of overweight and obesity: a review. Diabetes, Obesity and Metabolism, 25(1), 18-35.
https://doi.org/10.1111/dom.14863
Hamza, M., Papamargaritis, D., & Davies, M. J. (2024). Tirzepatide for overweight and obesity management. Expert Opinion on Pharmacotherapy, 1-19.
https://doi.org/10.1080/14656566.2024.2436595
le Roux, C. W., Zhang, S., Aronne, L. J., Kushner, R. F., Chao, A. M., Machineni, S., ... & Bunck, M. C. (2023). Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity, 31(1), 96-110.
https://doi.org/10.1002/oby.23612
Jin, X., Qiu, T., Li, L., Yu, R., Chen, X., Li, C., ... & Jiang, T. (2023). Pathophysiology of obesity and its associated diseases. Acta Pharmaceutica Sinica B, 13(6), 2403-2424.
https://doi.org/10.1016/j.apsb.2023.01.012
Lin, X., & Li, H. (2021). Obesity: epidemiology, pathophysiology, and therapeutics. Frontiers in endocrinology, 12, 706978.
https://doi.org/10.3389/fendo.2021.706978
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232.
DOI: 10.1056/NEJMoa2307563
Mahmoud, R., Kimonis, V., & Butler, M. G. (2022). Genetics of obesity in humans: a clinical review. International journal of molecular sciences, 23(19), 11005.
https://doi.org/10.3390/ijms231911005
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.
DOI: 10.1056/NEJMoa2206038
Wahab, R. A., & le Roux, C. W. (2023). A review of the evidence on cardiovascular outcomes from obesity treatment. Obesity Pillars, 7, 100071.
https://doi.org/10.1016/j.obpill.2023.100071
Farzam K, Patel P. Tirzepatide. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 20, 2024.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Weronika Zielińska , Joanna Wanat, Izabela Dzikowska, Agata Siejka, Daria Stefaniak; Aleksandra Warunek; Gabriela Gronowicz, Wojciech Homa, Michał Chról
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 168
Number of citations: 0
